Udita Sharma
Udita Sharma
Investment Engagement Manager
Helped 500+ investors build
their investment thesis.

India’s Healthcare Spending Is Skyrocketing And Smart Money Is Paying Attention

Private equity in India has always followed a predictable script. Consumer tech, real estate, infrastructure, these were the darlings of institutional investors. Healthcare, despite its obvious importance, was often seen as too slow-moving, too capital-intensive, or too dependent on government policies. But in the past few years, something has shifted.

Private equity firms are no longer circling around healthcare; they’re diving in. And they aren’t just backing large hospital chains or pharma giants—they are reshaping the very fabric of how Indians access and pay for healthcare. From specialty hospitals to diagnostics, from Tier 2 city expansion to digital-first healthcare platforms, the investment thesis is no longer just about scaling healthcare. It’s about owning the future of it.
There’s a simple reason why private equity is getting aggressive in this space: India’s healthcare spending is skyrocketing. As incomes rise, healthcare is becoming a non-negotiable expense. Indians spent over ₹9 lakh crore on healthcare in 2023, and that number is expected to grow at over 15% CAGR in the coming years . Private capital is chasing that growth, looking for scalable, high-margin models that don’t just serve the urban elite but also the vast middle class in Tier 2 and 3 cities.

Historically, hospital investments in India were a long game. Land acquisition, regulatory approvals, massive upfront capital, everything about it was slow. But a new investment playbook has emerged. Instead of building massive hospitals from scratch, investors are funding specialty chains that focus on high-demand procedures like oncology, nephrology, IVF, orthopedics—allowing them to turn profits faster. Instead of betting on metro-focused players, they are backing regional healthcare brands that are bringing affordable quality care to non-metro areas.

The diagnostics sector is seeing an equally aggressive transformation. India conducts over a billion diagnostic tests annually, yet much of this market is still unorganized. Investors have realized that the real opportunity isn’t just in labs, but in creating tech-enabled diagnostic networks that make high-quality testing available across cities. Deals in this space have surged, with firms acquiring stakes in pathology labs, imaging centers, and AI-driven diagnostic startups .

The shift isn’t just happening inside hospitals and labs. Private capital is reshaping how Indians pay for healthcare. For years, insurance penetration was abysmally low, with most Indians paying out-of-pocket for treatments. Today, a wave of health-fintech startups is changing that. From EMI-based payment models for hospital bills to subscription-based preventive care packages, private investors are betting big on healthcare financing solutions .

There’s also a massive push towards digital-first healthcare, where telemedicine, AI-driven diagnostics, and home healthcare are creating entirely new business models. Five years ago, most investors would have dismissed the idea that serious medical consultations could happen over a screen. Today, more than half of India’s teleconsultations are happening outside metro areas, proving that the demand for virtual healthcare is real and investable .

But perhaps the biggest reason why smart money is flowing into Indian healthcare is exit visibility. Unlike a decade ago, when hospital and pharma IPOs were rare, we are now seeing a clear pathway for investors to monetize their healthcare bets.

For investors, the equation is now simple. India is adding over 15 million new middle-class consumers every year, and healthcare is one of the first things they are willing to spend more on. The infrastructure is evolving, the tech is scaling, and the regulatory environment is becoming more investment-friendly.

This isn’t just another investment cycle. It’s a fundamental restructuring of how healthcare in India is built, funded, and delivered. And for those paying attention, it’s clear, the biggest healthcare deals of the decade won’t happen in metro hospitals, but in the fast-growing, tech-enabled, investor-backed ecosystem that is quietly taking over Indian healthcare .

Source – EY The AIdea of India 2025 – How Much Productivity Can GenAI Unlock in India

Frequently Asked Questions

Q: Why is private equity investing heavily in Indian healthcare?
A: Rising healthcare spending, scalable business models, and tech-driven innovations are attracting private capital.
Q: Which sectors within Indian healthcare are seeing the most investment?
A: Specialty hospitals, diagnostics, digital healthcare platforms, and health-fintech are top investment areas.
Q: How is healthcare financing evolving in India?
A: Investors are backing EMI-based hospital payments, subscription care packages, and expanding insurance penetration.
Q: What role does telemedicine play in India’s healthcare growth?
A: Telemedicine is expanding access, with over 50% of India’s virtual consultations now happening outside metros.
Q: Why are investors confident about exits in Indian healthcare?
A: Increased IPO activity in hospitals and pharma, along with high growth, provides strong exit opportunities.

Udita Sharma
Udita Sharma
Investment Engagement Manager
Helped 500+ investors build
their investment thesis.

TERMS OF USE

Thank you for your interest in our Website at https://unlistedintel.com/. Your use of this Website, including the content, materials and information available on or through this Website (together, the “Materials”), is governed by these Terms of Use (these “Terms”). By using this Website, you acknowledge that you have read and agree to these Terms.

NO OFFER, SOLICITATION OR ADVICE

Our site is provided for informational purposes only. It does not constitute to constitute (i) an offer, or solicitation of an offer, to

purchase or sell any security, other assets, or service, (ii) investment, legal, business, or tax advice, or an offer to provide such advice or (iii) a basis for making any investment decision.

The Materials are provided for informational purposes and have been prepared by Oister Global for informational purposes to acquaint existing and prospective underlying funds, entrepreneurs, and other company founders with Oister Global's recent and historical investment activities.

Please note that any investments or portfolio companies referenced in the Materials are illustrative and do not reflect the performance of any Oister Global fund as a whole. There is no obligation for Oister Global to update or alter any forward-looking statements, whether as a result of new information, future events, or otherwise.

PURPOSE LIMITATION AND ACCESS TO YOUR PERSONAL DATA:

We will only collect your personal data in a fair, lawful, and transparent manner. We will keep your personal data accurate and up to date. We will process your personal data in line with your legal rights. We use your name and contact details, such as email, postal address, and contact number to continue communications with you. We may also use your contact information to invite you to events we are hosting or to keep you updated with our news.

USE OF COOKIES OR SIMILAR DEVICES

We use cookies on our website. This helps us to provide you with a better experience when you browse our website and also allows us to make improvements to our site. You may be able to change the preferences on your browser or device to prevent or limit your device’s acceptance of cookies, but this may prevent you from taking advantage of some of our features.

MATERIAL

The material displayed on our site is provided “as is”, without any guarantees, conditions, or warranties as to its accuracy, completeness, or reliability. You should be aware that a significant portion of the Materials includes or consists of information that has been provided by third parties and has not been validated or verified by us. In connection with our investment activities, we often become subject to a variety of confidentiality obligations to funds, investors, portfolio companies, and other third parties. Any statements we make may be affected by those confidentiality obligations, with the result that we may be prohibited from making full disclosures.

MISCELLANEOUS

This Website is operated and controlled by Oister Global in India. We may change the content on our site at any time. If the need arises, we may suspend access to our site, or close it indefinitely. We are under no obligation to update any material on our site.

CONTACT INFORMATION

Any questions, concerns or complaints regarding these Terms should be sent to info@oisterglobal.com

Campaign btn